Why Myriad Genetics Bears Were Right Before The Drop

For Myriad Genetics shareholders, the loss over the past year was 43.2%, including dividends. If you had bought in back on 6 October 2025 expecting AI driven precision oncology, broader reimbursement and margin recovery to move the story closer to those bullish and bearish analyst fair values, the recent Q2 2026 revenue shortfall and guidance cut sharpen a narrower question: Which of those specific assumptions about growth, profitability and valuation did not adequately allow for what ultimately happened?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

The move put Myriad Genetics in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.

What You Would Have Been Weighing Up With Myriad Genetics

The shares cost US$7.99 at the start of the period, and anyone looking at Myriad Genetics then had to choose between two very different but reasonable stories.

On the bullish side, the August 2025 Narrative put Fair Value at US$14.33, 79% above the start price, hinging on 6.0% revenue growth, profit margins lifting to 13.8%, and a future P/E assumption of 12.4x within a 3 year window.

The May 2025 bear case still saw upside in oncology testing but set Fair Value at US$7.31, with progress threatened by rising payer pushback, high debt costs, and dependence on mature products like MyRisk and GeneSight.

What The Results Changed For The Myriad Genetics Thesis

Fresh Q2 2026 numbers gave Myriad Genetics holders a hard reference point. Revenue slipped from US$213.1 million in Q2 2025 to US$190.7 million, and full year guidance moved down to a midpoint of US$780 million, which challenged both the bullish growth and margin lift story. Net income loss narrowed from US$330.5 million to US$43.2 million, so profitability improved but remained unproven.

The key lesson is about timing and mix of progress. When a thesis leans on both revenue acceleration and margin repair, it is important to watch whether guidance, sales and net margin are moving together, rather than focusing on just one line item improving.

What You Would Be Paying For In Myriad Genetics Today

Myriad Genetics now trades at US$4.28, with this Narrative's Fair Value sitting above that quote based on its own set of assumptions rather than an agreed truth.

The argument focuses on Myriad Genetics using AI driven partnerships and reimbursement gains to reshape cancer testing economics. For that higher figure to be reached, a buyer today would need confidence that oncology volumes and pricing actually move in the way the Narrative assumes.

"Unique integration of AI, biomarkers, and tumor profiling through strategic partnerships positions the company to dominate precision oncology and capture outsized growth as standards shift. Accelerated R&D efforts and expanded reimbursement drive broader market adoption, supporting robust margin expansion and long-term growth in both provider and direct-to-consumer channels."

One Narrative disagrees with today's price. → See where this Narrative says Myriad Genetics should trade

Where Could You Get There Earlier?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 39% below our estimate - helps online marketplaces handle local payment collection, settlement and payout in emerging economies.
• Company 2 - 20% below our estimate - expands a solar hardware and software stack that project developers standardize on for utility projects.
• Company 3 - 40% below our estimate - wins complex public infrastructure contracts while upgrading construction technology to relieve labor and cost pressure.

Three companies from the same screener. Open all 27 potentially undervalued companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com